anacardio.comCrawled Oct 15, 2026
The page describes heart failure as a global public health problem, affecting more than six million people in the U.S. and nearly 100 million worldwide, and notes its effects on quality of life, hospitalizations and risk of death.
AnaCardio announced the completion of a €62.5 million Series B financing co-led by Novo Holdings and the Ljungström family office, with participation from Helsinn, Pureos Bioventures, Sound Bioventures, Industrifonden and Flerie.
AnaCardio completed a SEK 150 million Series A financing round co-led by Flerie Invest AB and Industrifonden, with 3B Future Health Fund also participating. The funding will advance drug candidate AC01 in heart failure.
AnaCardio AB appointed Patrik Strömberg as chief executive officer, effective September 1, 2021. He joined from a role as vice president of external innovation, sourcing and evaluation at Swedish Orphan Biovitrum AB (Sobi).
The U.S. Food and Drug Administration granted AnaCardio’s Investigational New Drug application for AC01, enabling expansion of its clinical development.
AnaCardio received approval for the GOAL-HF1 Phase 1b/2a study from authorities and ethics committees in Sweden, the Netherlands, Italy and the United Kingdom. The 28-day study evaluates oral AC01 in patients with heart failure.
AnaCardio announced that the first patient had been dosed in its GOAL-HF1 study of AC01 in patients with heart failure and reduced ejection fraction.
AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing drugs to treat heart failure.
AnaCardio AB lists its address in Solna, Sweden, and provides the contact email info@anacardio.com.
AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.